Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print International Study Suggests Carboplatin Could Be First-line Chemotherapy Drug For Ovarian Cancer

International Study Suggests Carboplatin Could Be First-line Chemotherapy Drug For Ovarian Cancer

August 14, 2002

Results of an international study in this week's issue of THE LANCET suggest that the drug carboplatin could become a first-line chemotherapeutic agent for the treatment of ovarian cancer. Carboplatin was found to be less toxic, although it had no overall survival benefit, compared with other drugs assessed in the study.

Ovarian cancer is the sixth most common cancer of women worldwide; around 165,000 people are diagnosed with the disease every year, and five-year survival for women with advanced disease is only around 30%. Treatment involves surgery (eg. total hysterectomy or removal of the ovaries) and postoperative chemotherapy.




Previous research has shown that both combinations of the chemotherapeutic drugs cyclophosphamide, doxorubicin, and cisplatin ( known as CAP) and use of carboplatin produce similar survival and progression-free survival rates. More recently, the taxane paclitaxel combined with carboplatin has become a widely accepted treatment for the disease. The International Collaborative Ovarian Neoplasm (ICON) Collaborators, led by Peter Harper, consultant medical oncologist at Guy`s Hospital in London, and Nicoletta Colombo, Associate Professor in Obstetrics and Gynaecology at the European Institute of Oncology in Milan, Italy, aimed to compare the safety and efficacy of paclitaxel plus carboplatin with a control of either CAP or carboplatin alone. The trial was coordinated by the MRC Clinical Trials Unit, London, UK.

2074 women with ovarian cancer from 130 centres in eight countries were randomly assigned paclitaxel plus carboplatin or control, the control (CAP or single-agent carboplatin) being chosen by the patients' physician before randomisation. Average follow-up was just over four years; the average survival (around three years) and average time to disease recurrence (around a year and a half) was similar among all women studied. Those given paclitaxel plus carboplatin had more serious side effects such as alopecia (hair loss), fever, and sensory neuropathy (loss of sensation in the skin) than other treatments.

Peter Harper comments: "The results of ICON3 suggest that, up to 5 years from treatment, single-agent carboplatin, CAP, and paclitaxel plus carboplatin are all safe and show similar effectiveness as first-line treatments for women requiring chemotherapy for ovarian cancer. Of these three treatments, carboplatin might be regarded as the preferred treatment because of its better toxicity profile."

In an accompanying Commentary (p 500), Martin Tattersall from Sydney University, Australia, refers to previous research which illustrated how patients with advanced ovarian cancer predominantly opted for chemotherapy which offered marginal survival benefit, rather than treatment which could provide better quality of life because of reduced toxicity. He concludes: "The proportion of women with advanced ovarian cancer who have a normal life expectancy remains low despite claims of major progress in treatment in the past few years.13,14 The creation and nurturing of large collaborative clinical trial groups in ovarian cancer will facilitate rapid accrual of the numbers of patients required to document improved outcomes which are possible with the treatment approaches now under evaluation."

Lancet



Related Ovarian Cancer Current Events and Ovarian Cancer News Articles Ovarian Cancer Current Events and Ovarian Cancer News RSS Ovarian Cancer Current Events and Ovarian Cancer News RSS
FDA approved leukemia drugs shows promise in ovarian cancer cells
The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found.

American Dietetic Association Releases Updated Position Paper Promoting and Supporting Breastfeeding
The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible.

Metals could forge new cancer drug
Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds.

Breast cancer patients with high risk gene diagnosed 6 years earlier than generation before
Women with a deleterious gene mutation are diagnosed with breast cancer six years earlier than relatives of the previous generation who also had the disease and/or ovarian cancer, according to new research from The University of Texas M. D. Anderson Cancer Center.

Cancer Predisposition From Gene Variant Shows Strong Gender Bias
Cancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias, researchers at the University of Cincinnati (UC) have demonstrated.

Medications Effective in Reducing Risks for Breast Cancer Can Also Cause Serious Side Effects
Three drugs that reduce a woman's chance of getting breast cancer also have been shown to cause adverse effects, according to a new report from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health & Human Services.

Scientists from University of Hawaii at Manoa find genetic marker
A new genetic marker associated with ovarian cancer risk was recently discovered by an international research group, led by scientists from the Cancer Research Genetic Epidemiology Unit in the United Kingdom.

New treatment in sight for ovarian cancer
In the future, women with metastatic ovarian cancer could be treated with a radioactive substance that can seek and destroy tumour cells.

Young early stage ovarian cancer patients can preserve fertility
A new study finds that young women with early-stage ovarian cancer can preserve future fertility by keeping at least one ovary or the uterus without increasing the risk of dying from the disease.

Estrogen-Dependent Switch Tempers Killing Activity of Immune Cells
The sex hormone estrogen tempers the killing activity of a specific group of immune cells, the cytotoxic T cells (CTLs), which are known to attack tumor cells and cells infected by viruses.
More Ovarian Cancer Current Events and Ovarian Cancer News Articles
Beating Ovarian Cancer: How To Overcome The Odds And Reclaim Your Life

Beating Ovarian Cancer: How To Overcome The Odds And Reclaim Your Life
by Chris Bledy (Author)

A diagnosis of Ovarian Cancer does not have to be a death sentence. Recent advances in medicine have made this once incurable disease treatable and manageable. You can beat advanced and even recurring, ovarian cancer. Simple but significant lifestyle changes can produce big results when it comes to healing.

Ovarian Cancer Awareness "Unite to Fight" Wristband Adult Size

Ovarian Cancer Awareness "Unite to Fight" Wristband Adult Size
by sci

Ovarian Cancer Awareness "Unite To Fight" Wristband adult size

A Guide to Survivorship for Women with Ovarian Cancer (A Johns Hopkins Press Health Book)

A Guide to Survivorship for Women with Ovarian Cancer (A Johns Hopkins Press Health Book)
by F. J. Montz MD KM FACOG FACS (Author), Robert E. Bristow MD FACOG (Author), Paula J. Anastasia RN MN OCN (Assistant)

This comprehensive guide to ovarian cancer offers a wealth of information to ease the physical, emotional, and psychic suffering of women with the disease. The authors -- two Johns Hopkins gynecologic oncologists and a gynecologic-oncology clinical nurse -- put particular emphasis on the concept of "survivorship," or living life well in the face of daunting uncertainties. They stress the importance of self-determination: the right of each patient to be informed, involved, and in control of her care.

Up-to-date information on diagnosis and treatment, including surgery, chemotherapy, radiation, pain management, and alternative therapies, forms the core of the book. But the authors' immense clinical experience also means they understand what women worry about and care about, and...

Ovarian Cancer Awareness 8" Ribbon Car Magnet

Ovarian Cancer Awareness 8" Ribbon Car Magnet
by sci

Ovarian Cancer Awareness 8" Ribbon Car Magnet

L'Oréal Paris Color of Hope OCRF (Ovarian Cancer Research Fund) Fundraising Sterling Silver Pavé CZ Bracelet

L'Oréal Paris Color of Hope OCRF (Ovarian Cancer Research Fund) Fundraising Sterling Silver Pavé CZ Bracelet
by Netaya

Sterling beauty with an equally beautiful message.

Its new, its exclusive and its absolutely beautiful. LOreal Paris is proud to present the Color of Hope Bracelet, a fundraising campaign, with 100% of all net profits ($5.00 per bracelet) benefiting The Ovarian Cancer Research Fund (OCRF).

Whether viewed as a circle representing life, endurance, love or seen as an "O" for ovarian cancer, the bracelet is a simple way for women everywhere to visibly and tangibly help in the fight against one of the world's most deadly of women's cancers.

The exclusive sterling silver Color of Hope bracelet features a rolo design chain with an "O" toggle clasp, adorned with pave cubic zirconias to give a beautiful brilliance. And to ensure that all women can adorn their wrists, the bracelet...

Ovarian Cancer Journeys: Survivors Share Their Stories To Help Others

Ovarian Cancer Journeys: Survivors Share Their Stories To Help Others
by Ayala Miron (Author)

"All of the research has reinforced that ovarian cancer is not a silent disease as was once thought and as is shown quite eloquently in this collection of stories.... The value of this collection of stories is that it helps raise awareness about symptoms, need for patient persistence, and the importance of being treated by a gynecologic oncologist."

Barbara A. Goff, MD
Professor and Co-Director, Division of Gynecologic Oncology University of Washington School of Medicine

Women of ages 17 to 78 join to tell their true stories.
Find out about the lessons they have learned along their ovarian cancer journeys; from symptoms to diagnosis, trough treatments, and survival.

Ovarian cancer facts:
Occurs in 1 out of 57 women 89% have symptoms at the early stages...

Ovarian Cancer Awareness Teal Ribbon Crystal Heart Necklace

Ovarian Cancer Awareness Teal Ribbon Crystal Heart Necklace
by CharmingChick

This is a beautiful new teal ribbon heart charm necklace that is the perfect way to show your support for Ovarian Cancer Awareness. The pendant measures about 5/8 of an inch tall and is made of genuine sterling silver. It has stunning teal Swarovski Crystal embedded in the front. Box chain measures about 16 inches long. This teal ribbon necklace would make a great gift or is a wonderful way to remember a loved one with Ovarian Cancer.

100 Questions & Answers About Ovarian Cancer, Second Edition

100 Questions & Answers About Ovarian Cancer, Second Edition
by Don S. Dizon (Author)

Whether you're a newly diagnosed ovarian cancer patient, a survivor, or a friend or relative of either, this book offers help. Completely updated, the new second edition of 100 Questions & Answers About Ovarian Cancer gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. Written by a gynecologic oncologist and a gynecologic surgeon, with actual patient commentary, this book is an invaluable resource for anyone coping with the physical and emotional turmoil of this frightening disease.

Ovarian Cancer Awareness Long Sleeve T-shirt Large White

Ovarian Cancer Awareness Long Sleeve T-shirt Large White
by Shop Zeus



100 Pack Teal Blue Ribbon Temporary Tattoos for Ovarian Cervical Uterine Cancer Awareness

100 Pack Teal Blue Ribbon Temporary Tattoos for Ovarian Cervical Uterine Cancer Awareness
by Palmetto Fundraising

Show your courage and support! These teal ribbon tattoos are perfect for your next awareness event. These tattoos make great inspirational giveaways. 100 tattoos per package. Teal ribbon design with clear sides. Approximately 1.5" x 2". These cancer awareness favors are perfect for your awareness fundraisers or event.

© 2009 BrightSurf.com